Skip to main content
    B

    BioLife Solutions Inc (BLFS)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $38.61
    +0.00 (+0.00%)

    Market Cap: $1.89B

    Last updated: Nov 06, 2026 at 4:00 PM ET

    BioLife Solutions Inc (BLFS) Financials: Revenue, Profit and Cash Flow

    Updated Aug 6, 2026. Financial statements from company filings, amounts in US dollars.

    BioLife Solutions reported revenue of $96.21M for the fiscal year ended Dec 31, 2025, up 28.9% from the year before. That year, net income was -$4.59M with a net margin of -4.8%, operating cash flow was $20.11M and free cash flow was $10.64M. The quarter ended Jun 30, 2026 had revenue of $28.47M and net income of $45.10M.

    Revenue and Margins

    The operating margin was -17.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $8.23M, a compound annual rate of 31.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$96.21M+28.9%64.6%-17.3%-4.8%
    Dec 2024$74.65M+9.7%67.1%-6.0%-27.0%
    Dec 2023$68.02M-10.8%60.7%-25.3%-100.0%
    Dec 2022$76.24M-36.0%61.5%-7.8%-183.4%
    Dec 2021$119.16M+147.8%31.1%-29.5%-7.5%
    Dec 2020$48.09M+75.7%57.1%-13.0%4.1%
    Dec 2019$27.37M+38.6%68.0%-0.8%-6.1%
    Dec 2018$19.74M+79.1%68.5%18.5%-126.7%
    Dec 2017$11.02M+34.0%61.2%-9.6%-22.8%
    Dec 2016$8.23MN/A58.1%-59.0%-97.7%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$96.21M$74.65M$68.02M$76.24M$119.16M$48.09M$27.37M$19.74M$11.02M$8.23M
    Cost of revenue$34.10M$24.55M$26.70M$29.33M$82.11M$20.65M$8.76M$6.22M$4.28M$3.45M
    Gross profit$62.12M$50.10M$41.32M$46.91M$37.05M$27.44M$18.61M$13.53M$6.75M$4.78M
    Research and development$7.57M$4.75M$5.51M$8.67M$11.82M$6.72M$3.17M$1.30M$1.19M$2.03M
    Operating income-$16.60M-$4.48M-$17.20M-$5.92M-$35.16M-$6.24M-$220.00K$3.66M-$1.06M-$4.85M
    Net income-$4.59M-$20.18M-$68.00M-$139.81M-$8.91M$1.98M-$1.66M-$25.00M-$2.52M-$8.04M
    EBITDA-$10.84M$4.20M$231.00K$10.78M-$22.01M$2.43M$14.40MN/A-$796.00K-$4.39M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$28.47M$27.50M$18.79M$28.07M$23.44M$22.05M$15.11M$21.39M$19.71M$18.43M-$22.50M$23.57M
    Gross profit$18.29M$17.50M$11.98M$17.92M$15.23M$14.80M$10.66M$13.99M$13.21M$12.24M$4.26M$11.99M
    Operating income$1.70M$27.00K$1.35M-$89.00K-$16.13M-$499.00K$542.00K-$418.00K-$1.31M-$3.29M$22.50M-$15.47M
    Net income$45.10M$1.19M$11.07M$621.00K-$15.84M-$448.00K$12.46M-$1.70M-$20.72M-$10.22M-$14.96M-$29.13M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $5.00M by $28.04M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$405.88M$399.49M$412.71M$450.23M$554.29M$234.83M$92.82M$45.47M$12.14M$7.93M
    Current assets$136.56M$148.76M$120.60M$138.45M$126.09M$114.71M$24.11M$37.56M$9.93M$4.63M
    Cash and equivalents$33.04M$91.54M$27.90M$19.44M$69.86M$90.40M$6.45M$30.66M$6.66M$1.41M
    Total liabilities$34.00M$50.58M$75.05M$86.04M$76.24M$29.58M$49.36M$30.84M$2.05M$4.76M
    Short-term debt$5.00M$10.94M$6.29M$3.95M$5.99M$3.25M$377.00K$0N/A$2.84M
    Long-term debtN/A$5.00M$17.56M$23.79M$6.35M$655.00KN/AN/A$0$2.84M
    Shareholder equity$371.89M$348.91M$337.66M$364.19M$478.05M$205.25M$43.45M$14.63M$10.09M$3.17M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$447.49M$400.91M$405.88M$392.08M$387.24M$395.14M$399.49M$381.65M$374.98M$401.60M$412.71M$411.15M
    Total liabilities$27.49M$28.68M$34.00M$38.34M$40.09M$42.52M$50.58M$56.19M$53.53M$68.20M$75.05M$79.14M
    Cash and equivalents$24.00M$22.82M$33.04M$29.48M$31.90M$66.94M$95.39M$23.98M$22.01M$29.69M$27.90M$19.23M
    Shareholder equity$420.00M$372.23M$371.89M$353.74M$347.15M$352.62M$348.91M$325.46M$321.44M$333.40M$337.66M$332.02M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 52.9% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$20.11M$8.43M-$12.50M-$8.49M-$4.59M$6.64M$1.21M$2.35M$605.00K-$4.33M
    Capital expenditures$9.48M$3.23M$6.38M$10.38M$8.38M$1.96M$675.00K$500.00K$144.00K$1.26M
    Free cash flow$10.64M$5.20M-$18.88M-$18.87M-$12.98M$4.68M$538.00K$1.85M$461.00K-$5.58M
    Dividends paidN/AN/AN/AN/AN/AN/A$0$436.00K$106.00K$0
    Share repurchasesN/AN/AN/A$131.00K$145.00K$6.20M$0N/A$52.00K$111.74K
    Investing cash flow-$71.54M$58.30M$17.84M-$58.12M-$13.19M-$24.71M-$27.02M-$6.50M-$144.00K$392.79K
    Financing cash flow-$10.92M-$6.78M$10.59M$16.32M-$2.78M$102.08M$1.60M$28.15M$4.80M$3.17M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow$6.35M-$491.00K$4.92M$6.10M$7.37M$1.73M$1.65M$4.80M$6.46M-$4.47M$2.31M-$4.38M
    Capital expenditures$1.04M$167.00K$4.26M$3.30M$1.74M$175.00K$762.00K$1.11M$995.00K$356.00K$981.00K$1.50M
    Free cash flow$5.30M-$658.00K$658.00K$2.80M$5.63M$1.55M$883.00K$3.69M$5.46M-$4.83M$1.33M-$5.88M
    Last 12 quarters

    Frequently Asked Questions About BLFS

    What is BioLife Solutions' annual revenue?

    BioLife Solutions reported revenue of $96.21M for the fiscal year ended Dec 31, 2025.

    How fast is BioLife Solutions' revenue growing?

    Revenue was up 28.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 8.1%.

    Is BioLife Solutions profitable?

    No. BioLife Solutions reported net income of -$4.59M for the fiscal year ended Dec 31, 2025, with a net margin of -4.8%.

    How much free cash flow does BLFS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $20.11M minus capital expenditures of $9.48M produced free cash flow of $10.64M.

    How much debt does BioLife Solutions have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $5.00M and cash and equivalents of $33.04M.